Comparative Pharmacology
Head-to-head clinical analysis: CALOMIST versus NASALCROM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CALOMIST versus NASALCROM.
CALOMIST vs NASALCROM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Calomist (calcium gluconate) provides calcium ions to stabilize cardiac cell membranes, correct hypocalcemia, and antagonize hyperkalemia-induced cardiotoxicity.
Cromolyn sodium stabilizes mast cells by inhibiting the release of histamine and other mediators of inflammation from sensitized mast cells. The exact molecular mechanism is not fully understood but may involve inhibition of calcium ion influx into mast cells.
Mist inhalation: 1-2 actuations (100-200 mcg) delivered orally via nebulizer every 6 hours as needed for bronchospasm; maximum 12 actuations per day.
One spray (5.2 mg) into each nostril 3-4 times daily (maximum 6 times daily).
None Documented
None Documented
Terminal elimination half-life: 4-6 hours; prolonged in renal impairment (up to 20 hours in anuria)
Terminal elimination half-life is 1-2 hours; clinically, due to local mast cell stabilization, systemic levels do not correlate with effect.
Renal: 90% unchanged; biliary/fecal: 10%
Primarily unchanged drug; renal excretion accounts for ~90% of elimination, with minor biliary/fecal excretion (<5%).
Category C
Category C
Mast Cell Stabilizer
Mast Cell Stabilizer